ArticleStem cell research & therapy2017
Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients.
Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Cell therapy for retinal degenerative disorders: a systematic review and three-level meta-analysis.Journal of translational medicine · 2024Pooled it
- Stem cell therapy for inherited retinal diseases: a systematic review and meta-analysis.Stem cell research & therapy · 2023Pooled it
- Human Stem Cell Transplantation for Retinal Degenerative Diseases: Where Are We Now?Medicina (Kaunas, Lithuania) · 2022Pooled it
- Safe CNV removal is crucial for successful hESC-RPE transplantation in wet age-related macular degeneration.Stem cell reports · 2025Trial
- Direct Chemical Reprogramming of Human Fibroblasts into Retinal Progenitor-like Cells for Ocular Delivery.Journal of functional biomaterials · 2026Article
- Review
- Stem cell-based therapies for inherited retinal diseases - Translational advances and clinical evidence: A review.Biomolecules & biomedicine · 2026Review
- Monitoring Gene Expression in Retina with synthetic serum markers.bioRxiv : the preprint server for biology · 2026Article
- Phase 1/2a Clinical Trial Protocol for Lentiviral Vector-Based Retinal Gene Therapy to Slow the Progression of Retinitis Pigmentosa.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Dynamic molecular and cellular characteristics of VSX2-positive retinal progenitor cells in human retinal organoids.Stem cell research & therapy · 2025Article
- Retinitis Pigmentosa: From Genetic Insights to Innovative Therapeutic Approaches-A Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Intraocular injectable hydrogels for the delivery of cells and nanoparticles.Materials today. Bio · 2025Review
- The neuroimmune interface in retinal regeneration.Progress in retinal and eye research · 2025Review
- Study protocol for a prospective natural history registry investigating the relationships between inflammatory markers and disease progression in retinitis pigmentosa: the RP-PRIMARY study.Japanese journal of ophthalmology · 2025Observational
- Mitochondrial diseases: from molecular mechanisms to therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Human Retinal Progenitor Cell (hRPC) Migration in Three-Dimensional (3D) Environments of Varying Stiffness and Composition.Journal of tissue engineering and regenerative medicine · 2025Article
- Tackling visual impairment: emerging avenues in ophthalmology.Frontiers in medicine · 2025Review
- Conditional Immortalization Using SV40 Large T Antigen and Its Effects on Induced Pluripotent Stem Cell Differentiation Toward Retinal Progenitor Cells.Stem cells and development · 2025Article
- Subretinal microglia support donor photoreceptor survival in rd1 mice.Stem cell research & therapy · 2024Article
- Unveiling Drivers of Retinal Degeneration in RCS Rats: Functional, Morphological, and Molecular Insights.International journal of molecular sciences · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinitis pigmentosa is a common genetic disease that causes retinal degeneration and blindness for which there is currently no curable treatment available. Vision preservation was observed in retinitis pigmentosa animal models after retinal stem cell transplantation. However, long-term safety studies and visual assessment have not been thoroughly tested in retinitis pigmentosa patients.
methodsIn our pre-clinical study, purified human fetal-derived retinal progenitor cells (RPCs) were transplanted into the diseased retina of Royal College of Surgeons (RCS) rats, a model of retinal degeneration. Based on these results, we conducted a phase I clinical trial to establish the safety and tolerability of transplantation of RPCs in eight patients with advanced retinitis pigmentosa. Patients were studied for 24 months.
resultsAfter RPC transplantation in RCS rats, we observed moderate recovery of vision and maintenance of the outer nuclear layer thickness. Most importantly, we did not find tumor formation or immune rejection. In the retinis pigmentosa patients given RPC injections, we also did not observe immunological rejection or tumorigenesis when immunosuppressive agents were not administered. We observed a significant improvement in visual acuity (P < 0.05) in five patients and an increase in retinal sensitivity of pupillary responses in three of the eight patients between 2 and 6 months after the transplant, but this improvement did not appear by 12 months.
conclusionOur study for the first time confirmed the long-term safety and feasibility of vision repair by stem cell therapy in patients blinded by retinitis pigmentosa.
trial registrationWHO Trial Registration, ChiCTR-TNRC-08000193 . Retrospectively registered on 5 December 2008.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.